Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

The COVID-19 pandemic is a global health crisis that poses a great challenge to the public
health system of affected countries. Safe and effective vaccines are needed to overcome this …

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

To the Editor—The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants in places where the virus is uncontained poses a global threat from the …

The rapid surge of SARS-CoV-2 cases due to the ‘variant of concern (VOC) 202012/01’,
also known as lineage B. 1.1. 7 or 20B/501Y. V1 in the UK, 1 in December 2020, raised …

SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due
to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-…

One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …

We report the development and evaluation of safety and immunogenicity of a whole virion
inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (…

The availability of a safe and effective vaccine would be the eventual measure to deal with
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have …